US2014154242A1PendingUtilityA1

Immunoglobulin variants and uses thereof

63
Assignee: GENENTECH INCPriority: Dec 16, 2002Filed: Sep 17, 2013Published: Jun 5, 2014
Est. expiryDec 16, 2022(expired)· nominal 20-yr term from priority
Inventors:Camellia W. AdamsAndrew ChanCraig CrowleyHenry B. LowmanGerald R. NakamuraLeonard G. Presta
A61P 9/14A61P 43/00A61P 7/06A61P 3/10A61P 5/40A61P 9/08A61P 5/00A61P 7/04A61P 9/10A61P 5/14A61P 37/08A61P 9/00A61P 37/06A61P 37/00A61P 37/02A61P 25/00A61P 29/00A61P 31/06A61P 27/02A61P 35/02A61P 35/00A61P 31/18A61P 27/16A61P 21/04A61P 15/08A61P 17/00A61P 13/12A61P 1/04A61P 17/02A61P 11/02A61P 17/14A61P 19/02A61P 1/00A61P 1/12A61P 1/16A61P 11/00A61P 11/06A61P 17/06A61P 11/08C07K 2317/52C07K 2317/732C07K 2317/56C07K 2317/55C07K 2317/24C07K 2317/565C07K 2317/72A61K 2039/505C12N 15/63C07K 16/2887C07K 2317/92C07K 2317/75C12N 5/16C07K 2317/41C07K 2317/73C07K 2317/734C07K 2317/567A61K 39/39558C07K 2317/522C07K 16/00C07K 16/28
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 81 . (canceled) 
     
     
         82 . A method of depleting B cells in vivo, comprising administering a humanized antibody that binds human CD20 to a mammal in an amount effective to deplete B cells, wherein the antibody comprises the VH sequence of SEQ ID NO. 8 and the VL sequence of SEQ ID NO. 2. 
     
     
         83 . The method of  claim 82 , wherein the antibody comprises the heavy chain and light chain amino acid sequences of SEQ ID NO. 39 and 40, respectively. 
     
     
         84 . The method of  claim 82 , wherein the antibody comprises the light chain and heavy chain amino acid sequences of SEQ ID NO. 40 and 41, respectively. 
     
     
         85 . The method of  claim 82 , wherein the antibody or the antigen-binding fragment is administered by intravenous infusion. 
     
     
         86 . The method of  claim 82 , wherein the antibody is administered subcutaneously. 
     
     
         87 . The method of  claim 82 , wherein the mammal is a human. 
     
     
         88 . The method of  claim 82 , wherein the peripheral B cells are depleted in the mammal. 
     
     
         89 . The method of  claim 82 , wherein the peripheral B cells are partially depleted. 
     
     
         90 . A method of depleting B cells in vivo, comprising administering an antigen-binding fragment of a humanized antibody to a mammal in an amount effective to deplete B cells, wherein the antigen-binding fragment comprises the CDR1 sequence of SEQ ID NO. 10, the CDR2 sequence of SEQ ID NO. 11, and the CDR3 sequence of SEQ ID NO. 12 in the heavy chain, and the CDR1 sequence of SEQ ID NO. 4, the CDR2 sequence of SEQ ID NO. 5, and the CDR3 sequence of SEQ ID NO. 6 in the light chain; wherein the humanized antibody comprises the heavy and light chain amino acid sequences of SEQ ID NO. 39 and 40, respectively. 
     
     
         91 . The method of  claim 90 , wherein the antigen-binding fragment is administered by intravenous infusion. 
     
     
         92 . The method of  claim 90 , wherein the antigen-binding fragment is administered subcutaneously. 
     
     
         93 . The method of  claim 90 , wherein the mammal is a human. 
     
     
         94 . The method of  claim 90 , wherein the peripheral B cells are depleted in the mammal. 
     
     
         95 . The method of  claim 90 , wherein the peripheral B cells are partially depleted.

Join the waitlist — get patent alerts

Track US2014154242A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.